Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘T790M’

With the sheer breadth and depth of immuno-oncology data being presented at even the American Association for Cancer Research (AACR), several readers were prompted to write in and ask:

“Is this the end of the road for TKI therapies? Should we even bother to continue working on these agents?”

Good question.

There was actually quite a bit of interesting data on regular novel targeted therapy to discuss, although I do concede that much of the mass media news focusing on the immuno-oncology tsunami in Philadelphia effectively drowned out targeted therapies and the results coming out in that space.

Reading Market Philly Chocolate TowerTo maintain the balance between novel targeted agents and immunotherapy, here’s a review of some of the interesting new developments that I came across at AACR, from both the poster halls, as well as some of the thought leaders in this space.

When you stack up the emerging evidence in several tumour subsets, there are quite a few tasty morsels that are worthy of further discussion!

I’d like to take this opportunity to extend a warm welcome to all the new subscribers who took advantage of the AACR Special Offer to continue their education and learning about the exciting new developments in cancer research.  Thank you for joining our conference coverage service, we really appreciate it.

To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content. 

2 Comments

Clovis Oncology RociletinibThe potential of Clovis Oncology’s EGFR inhibitor rociletinib (formerly CO-1686) to treat T790M negative non-small cell lung cancer (NSCLC) was one of the interesting talking points of the recent JP Morgan Healthcare conference in San Francisco (JPM15).

At the JP Morgan Healthcare Conference (JPM15), Clovis presented updated data that shows some efficacy in those NSCLC patients who no longer respond to an EGFR inhibitor, but don’t have a T790M mutation (T790M negative).  Both AstraZeneca’s competitor compound, AZD9291, and rociletinib shown considerable activity in those EFGR resistant patients who develop a T790M mutation and it’s likely they will both soon be approved in this indication, based on the encouraging data seen to date.

However, what is surprising and could be a key differentiation factor for Clovis, is if there is sufficient efficacy in T790M negative patients for use of the drug in this indication.

In this post, we discuss the potential of rociletinib in NSCLC T790M negative patients, whether thought leaders might use the drug in this indication, and delve deeper into the science behind the efficacy seen.

To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content. 

It’s been a long 14+ hours here on the first day of ECCO in Amsterdam and I’m starting to flag a little. The fun part of being in Amsterdam is renting an apartment, living like a local and cycling to/from the conference centre on rickety Dutch bicycles!

That said, having been aghast at the poor wifi and frustrated with nearly not being allowed in a key session over badge confusion, plus scheduling of multiple key sessions at once, we decided to make the best of it and be selective. This morning, for example, I ran from lung to melanoma to breast to the  poster hall and back again to a lung session. Pieter had the luxury of enjoying the prostate cancer session in comparison!  By 6pm the BMS corporate symposia on immunotherapy was out – the brain was dazed and jetlagged, the car needed fuel (preferably of the rocket variety) and also a glass of wine!

We will post some more detailed notes later, but today I wanted to offer some top line thoughts on some of the highlights:

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

error: Content is protected !!